Aim: Activating somatic mutations in p110α catalytic subunit of PIK3-kinase (PIK3CA) are present about 40% breast cancers (BC), and involved oncogenesis cancer growth. PIK3CA inhibitor therapy is approved for patients with advanced HR+/HER2- endocrine-resistant BC mutations. Such targeted improved patient disease-free survival. Method: Analyses gene were performed five University Hospital Cente...

Activation of the PI3K–AKT–mTOR pathway occurs in several human cancers, including hormone receptor (HR)-positive breast cancer (BC) where is associated with resistance to endocrine therapy and disease progression. In BC, most common alteration represented by PIK3CA oncogenic mutations. These mutations can occur throughout domains p110α catalytic subunit, but majority are found helical kinase (...